Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey

• Published in: Indian journal of medical research (New Delhi, India : 1994) Vol. 155; no. 1; pp. 123 - 128
• Main Authors: Kaur, Sukhpal, Singh, Ajay, Saini, Sushma, Rohilla, Latika, Kaur, Jasvir, Chandi, Anadeep, Kaur, Gurpreet, Singh, Manjeet, Kumar, Pramod, Soni, Shiv, Kajal, Kamal, Naik, Naveen, Malhotra, Pankaj, Verma, Sanjay, Gupta, Madhu, Devnani, Mahesh, Das, Karobi, Pandav, S, Puri, G
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01-01-2022; Scientific Scholar
• Subjects: Coronaviruses; Cross-sectional studies; Vaccines; Adverse events - ChAdOx1 nCoV-19 - coronavirus disease 2019 - healthcare professionals - side effects - vaccination
• ISSN: 0971-5916
• DOI: 10.4103/ijmr.ijmr_1221_21

Background & objectives: The safety of the ChAdOx1 nCoV-19 vaccine is a cause of concern for many who have been vaccinated. The people have multiple concerns and fear regarding the adverse events of the vaccine. Thus, this study was undertaken to establish the safety profile of ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) among the healthcare professionals.
Methods: This was a descriptive cross-sectional survey. After taking clearance from the institutional ethics committee 1500 healthcare professionals, who had their vaccination in the past two weeks were selected. They were provided with an online survey proforma regarding adverse events following immunization (AEFIs) of COVID-19 vaccine developed using google forms with an informed consent form affixed to it.
Results: A total of 1036 individuals participated in the study. The mean and median (inter quartile range) age of the participants was 37.7 ±11.25 and 35 (29-46) yr, respectively. Of these, 52.1 per cent were female, 29.3 per cent were doctors, 33.4 per cent were nurses and 9.5 per cent were paramedical staff. Forty six per cent participants experienced one or more minor AEFIs such as pain, tenderness, redness, etc. at the injection site. Fatigue (31.75%), generalized feeling of unwell (28.57%), muscle pain (23.16%) and fever (21.71%) were the most commonly reported systemic AEFIs followed by headache (20.07%), dizziness (10.03%) and joint pains (15.25%). Most of them experienced these AEFIs within 24 h of the first dose of administration. About 42 per cent of the participants took oral antipyretics/analgesics for managing the AEFIs.
Interpretation & conclusions: ChAdOx1 nCoV-19 Corona Virus Vaccine was found to be associated with mild local and systemic AEFIs that were more common after the first dose as compared to the second dose. There adverse events could be dealt with oral over-the-counter medications, with no requirement of hospitalization.